{"brief_title": "An Open-Label Safety Study of Oral Ganciclovir Maintenance Treatment of CMV Retinitis in People With Limited Venous Access", "brief_summary": "To provide oral ganciclovir to patients who require maintenance for control of cytomegalovirus (CMV) retinitis, but who lack patent permanent central venous access for long-term administration of intravenous drugs.", "detailed_description": "Patients receive oral ganciclovir as maintenance. Patients enrolled at time of closure of enrollment will receive 2 months of study drug and undergo follow-up.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Ganciclovir", "criteria": "Inclusion Criteria Patients must have: - AIDS. - Stable CMV retinitis. - Treatment with IV ganciclovir or IV foscarnet for at least 18 of the past 21 days. - No permanent central IV catheter at present. - Had a permanent central IV catheter removed two or more times within the past 6 months due to catheter infection or thrombosis. - Consent of guardian if less than legal age of consent. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: - Require continuation of concomitant medications precluded by this protocol. Concurrent Medication: Excluded: - Intravitreal anti-CMV treatment. - Any other concomitant medications precluded by the protocol. Patients with the following prior condition are excluded: History of hypersensitivity to acyclovir or ganciclovir.", "gender": "All", "minimum_age": "13 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002135.xml"}